Hanmi files phase 1 FDA IND for their next-gen obesity drug
By Son, Hyung-Min | translator Kim, Jung-Ju
24.04.01 14:04:59
가나다라
0
This represents the second IND submission following the submission to the Ministry of Food and Drug Safety (MFDS)...Hanmi aims to commercialize the drug by 2030
Hanmi will present the research outcomes, including weight management and improvements in cardiovascular diseases, at the 2024 American Diabetes Association (ADA) conference
▲Hanmi Obesity Pipeline.
Hanmi Pharmaceutical announced on the 1st that it submitted an investigational new drug (IND) to the U.S. FDA on March 29 for its triple-agonist (HM15275), a next-generation obesity drug. Its IND includes a trial goal to assess drug tolerance, pharmacokinetics, and pharmacodynamics of HM15275 in healthy adults and patients with obesity.
Hanmi aims to commercialize HM15275 by 2030. On February 29, Hanmi submitted an IND to the Ministry of Food and Drug Safety (MFDS) in Korea and is actively pursuing clinical development.
HM15275 is optimized to bind to glucagon-like peptide-1 (GLP-1), gastric inhibitory peptide (GIP), and glucagon (GCG). It is anticipated that HM15275 will have
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)